A Phase I Dose Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy With Biomarker Analysis in Patients With HER2 (human estrogen receptor 2)-Overexpressing Breast Cancer.
Phase of Trial: Phase I
Latest Information Update: 07 Apr 2014
At a glance
- Drugs Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 22 Jan 2013 Planned end date (Nov 2014) added as reported by ClinicalTrials.gov.
- 22 Jan 2013 Planned number of patients changed from 15 to 53 as reported by ClinicalTrials.gov.